Leap Investments’s Mustang Bio MBIO Stock Holding History

Leap Investments’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$55K	Buy	+23	New	+$53.8K	0.04%	381

Other funds holding MBIO

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Leap Investments's MBIO Position: Q2 2020 in Review

Leap Investments opened a new position in Mustang Bio (MBIO) in Q2 2020: 23 shares worth $55K. The stake represents 0.04% of the portfolio and ranks #381 among its holdings.

73 funds tracked by Wall St. Rank hold MBIO as of Q2 2020.

Leap Investments held 23 shares of Mustang Bio worth $55K as of Q2 2020.
Mustang Bio was a new Leap Investments position in Q2 2020.
Mustang Bio made up 0.04% of Leap Investments's portfolio in Q2 2020, its #381 holding.
73 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.